# CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)

> **NCT04060407** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)**

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** CD24Fc
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04060407
- **Lead sponsor:** Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-06-15
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2021-06-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04060407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04060407, "CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04060407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*